Neboglamine is a glutamic acid derivative that appears to facilitate the effect of glycine on NMDA receptors, possibly at a separate allosteric site. In a recent preclinical study [38], neboglamine appeared to promote neuronal growth as measured by expression of Fos-like immunoreactivity, particularly in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus. The pattern was most similar to effects produced by D-serine and, to a lesser extent, clozapine. Behaviorally, neboglamine also appeared to at least partially attenuate the effects of the NMDA receptor antagonist PCP on hyperlocomotion and rearing behavior. The authors also reported that phase I trials have been successfully completed in humans and that they planned to move forward with proof of concept trials in schizophrenia patients.
